Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-associated antigens presented by MHC class I/II (peptide-MHC or pMHC complexes) represent a crucial class of therapeutic targets in cancer immunotherapy. Under physiological conditions, intracellular proteins are degraded by the proteasome into short peptide fragments, which are then loaded onto major histocompatibility complex (MHC) class I or II molecules for presentation on the cell surface. In malignant cells, aberrantly expressed, mutated, or overexpressed proteins (such as cancer-testis antigens, neoantigens, or lineage-specific proteins) are presented as tumor-associated antigens (TAAs) within the MHC groove. This presentation provides a 'window' into the intracellular proteome, allowing the adaptive immune system to detect and eliminate cancer cells.
Therapeutic strategies targeting these pMHC complexes include T-cell receptor-engineered T-cell (TCR-T) therapies and soluble bispecific biologics, such as immune-mobilizing monoclonal T-cell receptors against cancer (ImmTACs) and T-cell receptor-mimic (TCRm) antibodies. These modalities bypass the limitations of traditional chimeric antigen receptor (CAR) therapies, which are restricted to cell-surface proteins, thereby vastly expanding the pool of targetable tumor antigens. However, targeting pMHC complexes presents unique challenges, including strict HLA restriction (requiring patient matching to specific HLA alleles), potential for severe on-target, off-tumor toxicities, and the risk of lethal cross-reactivity with similar self-peptides presented on healthy tissues.
T-cell redirection via bispecific T-cell engagers (ImmTACs) or adoptive cell transfer of TCR-engineered T-cells (TCR-T) to recognize specific peptide-MHC complexes and induce tumor cell lysis.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor-associated antigen peptide-MHC complex (pMHC).